Pharmaceuticals 2013, 6(4), 536-545; doi:10.3390/ph6040536
Article

Toxicity Studies on Novel N-Substituted Bicyclo-Heptan-2-Amines at NMDA Receptors

1 Department of Biological Sciences, Misher College, University of the Sciences, Philadelphia, PA 19104, USA 2 Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA 19104, USA 3 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Tandogan 06100, Ankara, Turkey
* Author to whom correspondence should be addressed.
Received: 25 January 2013; in revised form: 9 April 2013 / Accepted: 9 April 2013 / Published: 12 April 2013
(This article belongs to the Special Issue NMDA Receptor Antagonists for Treatment of CNS Disorders)
PDF Full-text Download PDF Full-Text [1046 KB, uploaded 12 April 2013 14:28 CEST]
Abstract: Several novel norcamphor derivatives were designed and synthesized as uncompetitive NMDA receptor antagonists at the phencyclidine (PCP) binding site. Such compounds have potential as ligands for understanding and possibly the treatment of several neurodegenerative disorders and other glutamate-dependent disorders. We examined the toxic effects of the compounds as compared with memantine, an NMDA receptor antagonist that is FDA approved for treatment of Alzheimer’s disease, by testing these compounds on two cell lines: MDCK (to mimic blood brain barrier) and N2a (a neuronal cell line). The compounds showed toxicity profiles similar to those of memantine i.e., dose dependence above 100 μM and IC50 values above 150 μM for each cell line. It is known that the serum level of memantine under therapeutic conditions in patients is about 1 µM, indicting these compounds could have acceptable therapeutic indexes. 2-Phenyl-N-(2-(piperidin-1-yl) ethyl)bicyclo[2.2.1]heptan-2-amine (5a) was found to possess acceptable toxicity profiles in both cell lines. Interestingly, this was the compound identified as a good lead in our previous studies based on binding and anticonvulsant (MES) activity studies. It has thus emerged as an excellent lead compound for further studies.
Keywords: NMDA receptor antagonist; neurodegeneration; cytotoxicity; MDCK and N2a cells

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Coleman, N.; Ates-Alagoz, Z.; Gaye, B.; Farbaniec, M.; Sun, S.; Adejare, A. Toxicity Studies on Novel N-Substituted Bicyclo-Heptan-2-Amines at NMDA Receptors. Pharmaceuticals 2013, 6, 536-545.

AMA Style

Coleman N, Ates-Alagoz Z, Gaye B, Farbaniec M, Sun S, Adejare A. Toxicity Studies on Novel N-Substituted Bicyclo-Heptan-2-Amines at NMDA Receptors. Pharmaceuticals. 2013; 6(4):536-545.

Chicago/Turabian Style

Coleman, Natalia; Ates-Alagoz, Zeynep; Gaye, Boyenoh; Farbaniec, Michelle; Sun, Shengguo; Adejare, Adeboye. 2013. "Toxicity Studies on Novel N-Substituted Bicyclo-Heptan-2-Amines at NMDA Receptors." Pharmaceuticals 6, no. 4: 536-545.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert